Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: 11 - What They Never Told You

Should You Invest in Johnson & Johnson (JNJ) Following Q3 Results

Johnson & Johnson’s (JNJ) third-quarter results impressed investors, as its earnings and revenue beat Wall Street estimates. Should investors consider investing in the stock following the solid third-quarter results? Read on to learn my view….

StockNews.com

3 Dividend Aristocrats to Defend Your Portfolio in Q4

In the midst of economic uncertainty, look to the likes of Procter & Gamble, Coca-Cola, and Johnson & Johnson as steadfast investment options, offering relative stability and reliable income for Q4 2023 and beyond.

Barchart

How big companies from EY to Johnson & Johnson are learning to master AI prompts

Embracing AI is the easy part—firms have already moved on to harder parts like making AI actually work for their business.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Johnson & Johnson (JNJ) vs. Madrigal Pharmaceuticals (MDGL): Which Pharma Stock Is a Worthier October Investment?

With an aging population worldwide, the growing prevalence of chronic diseases, new drug discoveries and rapid digital advancements, the outlook for the pharmaceutical sector remains optimistic. Pharma stocks Johnson & Johnson (JNJ) and Madrigal Pharmaceuticals (MDGL) will likely benefit from the industry’s bright prospects. But which of these stocks is…

StockNews.com

Generative AI is top of mind for all types of leaders, from Treasury Secretary Janet Yellen to J&J CEO Joaquin Duato

This week’s episode of Fortune‘s Leadership Next podcast features conversations from the Fortune CEO Initiative conference.

Fortune

Three Stocks To Help You Through the Financial Roller Coaster!

The Middle East is back in focus as tensions broke. But, what can investors own to weather the storm?

Barchart

Travis Kelce shakes off Aaron Rodgers dig: ‘I’m fully comfortable with him calling me Mr. Pfizer’

Mr. Pfizer and his mustache are doing just fine.

USA Today Sports Media Group

Read news from The Economist, FT, and more,
with one subscription

Chiefs’ Travis Kelce Responds to Aaron Rodgers’s ‘Mr. Pfizer’ Jab

“Who knew I’d get into the vax wars with Aaron Rodgers, man?”

Sports Illustrated

Aaron Rodgers oddly called Travis Kelce ‘Mr. Pfizer’ despite playing for the Johnson & Johnson heir

Aaron Rodgers can be such a dork, man.

USA Today Sports Media Group

In rare interview, J&J CEO Joaquin Duato opens up about Baby Powder cancer lawsuits and the future of Kenvue

J&J CEO Joaquin Duato's interview on Baby Powder cancer lawsuits, Kenvue, and the COVID vaccine.

Fortune

Johnson & Johnson Stock Looks Like Good Value Now

Johnson & Johnson stock (JNJ) recently spun off its consumer Kenvue business, which trades separately under the symbol KVUE. However, JNJ stock has dipped and now looks like good value.

Barchart

Protect Your Returns With These 3 Dividend Kings!

Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss!

Barchart

Protect Your Returns With These Three Dividend Kings!

Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss!

Barchart

Lawyers lose in better deal for pelvic mesh victims

A law firm that ran two class actions for women harmed by pelvic mesh implants will lose out on a $38.5 million cut of $405 million in settlement funds.

AAP

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

This J&J exec sold Tylenol and Listerine. Now she runs its $27B medtech business

Ashley McEvoy pivoted from over-the-counter products to medical devices.

The Independent UK

Johnson & Johnson is getting rid of its script logo after more than 130 years

Johnson & Johnson is signing off on a new logo, more than 130 years after creating the old one

The Times of India

Cricketer Harmanpreet Kaur on TIME100 NEXT 2023 list of emerging leaders

NEW DELHI: Three notable Indians, including cricketer Harmanpreet Kaur, have earned a spot on TIME magazine's prestigious "2023 TIME100 Next: the Emerging Leaders Shaping the World" list. The list also featured Nandita Venkatesan and Vinu Daniel. It also featured Indian-origin Nabarun Dasgupta.

Reason

Fake Sudafed Is Bullshit, Just As You Suspected

Legal restrictions on pseudoephedrine have not reduced meth use, but they have driven people with colds or allergies toward substitutes that seem to be completely ineffective.

Get all your
news in one place.

100's of premium titles.
One news app.

WEKU

The FDA asked advisers to take another look at phenylephrine, which became the main drug in over-the-counter decongestants when medicines with an older ingredient were moved behind pharmacy counters.

Chicago Sun-Times

Advisers to the Food and Drug Administration voted unanimously on Tuesday against the effectiveness of the key drug phenylephrine found in popular versions of Sudafed, Dayquil and other medications stocked on store shelves.

The Independent UK

Government advisers say the leading decongestant used by millions of Americans to treat nasal congestion doesn't actually work

Barchart

Unusual Options Activity in Johnson & Johnson Post Its Kenvue Spinoff Highlights Its Value

An unusual number of out-of-the-money put options in Johnson & Johnson come after the Aug. 30 spinoff of its consumer Kenvue business. This could be a good income play for short-put traders.

Salon

About the new drug pricing negotiations

The first eligible drugs treat diabetes, blood clots, blood cancers, arthritis and heart disease

Chicago Sun-Times

5 things consumers need to know about Medicare’s new drug-pricing negotiations, how they’ll affect you

This could help people whose Medicare drug plans require big copayments. But the main relief will come from part of the Inflation Reduction Act that caps drug spending by Medicare recipients at $2,000 a year starting in 2025.

The Guardian - UK

Cost of tuberculosis treatment halved in deal to permit generic versions

Johnson & Johnson’s year-long deal on life-saving drug bedaquiline is seen as critical move in campaign against disease

1 … 10 11 12 13

People

Dipanjan BanchurSince

722 stories

Harmanpreet Kaur

599 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.